Treatment Strategy and Building Your Care Team

Because TRIM22-related IBD is a complex condition that bridges the gap between gastroenterology and immunology, it cannot be managed by a single doctor. Your child’s care requires a “team of teams”—a group of specialists who collaborate to treat both the gut inflammation and the underlying immune system defect ^[1][2].

Your Multidisciplinary Care Team

A complete care team for monogenic IBD typically includes:

• Pediatric Gastroenterologist: Focuses on the health of the intestinal lining and managing symptoms like diarrhea and bleeding ^[1].
• Immunologist: Monitors the immune system’s functions, helping to prevent and treat the unusual infections common in TRIM22 variants ^[3].
• Geneticist: Helps interpret genetic reports and provides guidance on what the variant means ^[4].
• Infectious Disease (ID) Specialist: Manages complex bacterial or viral infections ^[2].
• Pediatric Colorectal Surgeon: Evaluates and manages severe perianal disease, which requires highly specialized surgical care ^[1].
• Registered Dietitian: Monitors growth and helps manage the high-calorie needs required for healing ^[1].

The Treatment Approach

In standard IBD, doctors often follow a predictable ladder of medications. However, in monogenic conditions like TRIM22, standard VEO-IBD is heterogeneous and care must be individualized.

1. Conventional Therapies: Medications like steroids or 5-ASAs (mesalamine) are often tried. While steroids can help “calm the fire” of a flare, children with VEO-IBD are more likely to become steroid-dependent or steroid-resistant, and these are not obligatory first steps ^[5].
2. Biologics: These are targeted medications like infliximab (anti-TNF) or ustekinumab (anti-IL12/23). In broad VEO-IBD cohorts, some children achieve remission, but a general response rate from mixed VEO-IBD cohorts cannot predict response in TRIM22-related disease ^[6][7].
3. Targeted Pathway Therapy: Research into the TRIM22-NOD2 pathway is ongoing. While scientists are investigating ways to modulate interferon and NF-kappaB signals, you must not start, stop, or seek an off-label immune therapy without your treating team ^[8][9].

Considering Stem Cell Transplant (HSCT)

Hematopoietic Stem Cell Transplant (HSCT) is sometimes discussed for monogenic IBDs (like IL-10 receptor deficiency) where it can be curative ^[10][11]. However, for TRIM22, there is no established indication or protocol.

• Potential Benefits: If the disease is caused primarily by immune cells (hematopoietic), a transplant may help restore normal immune function ^[10].
• Significant Risks: HSCT is a highly hazardous intervention. In broad monogenic IBD cohorts (not specific to TRIM22), severe infections and Graft-versus-Host Disease (GVHD)—where the new immune cells attack the child’s body—are frequently reported. HSCT also carries risks of transplant-related mortality, organ injury, and graft failure ^[12].
• The TRIM22 Uncertainty: Because so few cases of TRIM22 exist, the degree of predictability established for other genes does not exist here. The hematopoietic-versus-epithelial distinction remains uncertain ^[13][14]. Any consideration of HSCT requires a formal risk-benefit discussion with an expert transplant center ^[3].

How to Vet Your Specialists

When meeting with a potential specialist, it is important to gauge their experience with Very-Early-Onset IBD. You can ask:

• “How many patients with single-gene (monogenic) IBD have you treated?”
• “Do you have a formal process for collaborating with immunology and genetics?”
• “If our child becomes resistant to standard biologics, what is your center’s philosophy on experimental or targeted therapies?”
• “Does your center participate in VEO-IBD research registries (like the NEOPICS group)?” ^[1]

This journey requires a team that is not only expert in their field but also willing to admit when they are in uncharted territory and consult with national experts ^[1].